Takeda Pharmaceutical Company Limited (TKD.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Milano Furuta
|
CFO & Director | 1.24M | -- | 1978 |
|
Dr. Andrew S. Plump M.D., Ph.D.
|
President of Research & Development and Representative Director | 2.72M | -- | 1965 |
|
Ms. Julie Kim
|
CEO, President & Director | -- | -- | 1970 |
|
Dr. Seigo Izumo
|
Chair of Management Board | -- | -- | -- |
|
Mr. Haruhiko Hirate
|
Member of Management Board | -- | -- | 1957 |
|
Mr. Salvatore Alesci M.D., Ph.D.
|
Member of Management Board and Head of R&D Global Science & Biomedical Policy | -- | -- | 1975 |
|
Michael Fox
|
Chief Operating Officer | -- | -- | -- |
|
Norimasa Takeda
|
Chief Accounting Officer & Corporate Controller | -- | -- | -- |
|
Mr. Iwaaki Taniguchi
|
Senior Vice President of Corporate Finance & Controlling Department | -- | -- | -- |
|
Mr. Gabriele Ricci
|
Chief Data & Technology Officer | -- | -- | 1978 |
Takeda Pharmaceutical Company Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 47,029
Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Corporate Governance
Upcoming Events
January 28, 2027 at 9:00 PM UTC
Takeda Pharmaceutical Company Limited Earnings Date
March 30, 2027 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available
